REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Antigen, Epitope, Or Other Immunospecific Immunoeffector (e.g., Immunospecific Vaccine, Immunospecific Stimulator Of Cell-mediated Immunity, Immunospecific Tolerogen, Immunospecific Immunosuppressor, Etc.) > Amino Acid Sequence Disclosed In Whole Or In Part; Or Conjugate, Complex, Or Fusion Protein Or Fusion Polypeptide Including The Same Amino Acid Sequence Disclosed In Whole Or In Part; Or Conjugate, Complex, Or Fusion Protein Or Fusion Polypeptide Including The SameAmino Acid Sequence Disclosed In Whole Or In Part; Or Conjugate, Complex, Or Fusion Protein Or Fusion Polypeptide Including The Same patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/02/07 - 20070178114 - Novel kallikrein gene The invention relates to nucleic acid molecules, proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecule. ... 08/02/07 - 20070178113 - Superantigen conjugate This invention relates to treatment of multiple sclerosis using an immunomodulatory construct including a T cell binding defective superantigen coupled to one or more myelin-associated proteins, peptides, or functionally equivalent variants thereof. ... 07/26/07 - 20070172491 - Vaccine composition comprising an immunoadjuvant compound consisting of a rho gtpase family activator This invention is based on the experimental finding that activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine. This invention concerns a vaccine composition including an immunoadjuvant compound, wherein the immunoadjuvant compound consists of a ... 07/19/07 - 20070166318 - Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of ... 07/12/07 - 20070160623 - Innate immune system-directed vaccines The present invention provides novel vaccines, methods for the production of such vaccines and methods of using such vaccines. The novel vaccines of the present invention combine both of the signals necessary to activate native T-cells—a specific antigen and the co-stimulatory signal—leading to a robust and specific T-cell immune response. ... 07/12/07 - 20070160622 - Method for assembling a polymer-biologic delivery composition A one-step method for assembly of delivery compositions for one or more antigens or therapeutic biologics is based on non-covalent affinity capture of molecules from solution using a biodegradable polymer having functional groups to which the affinity ligand binds. The polymer-bound affinity complex, which includes the molecule(s) of interest is ... 07/12/07 - 20070160621 - Heat shock proteins from mycobacterium leprae and uses thereof The present invention is directed to heat shock proteins from Mycobacterium leprae as well as their encoding polynucleotides and vectors and host cells containing these polynucleotides. These heat shock proteins and their encoding polynucleotides are useful in detection of Mycobacterium leprae. In addition, the heat shock protein can be used ... 07/05/07 - 20070154488 - Compositions and methods for the therapy and diagnosis of lung cancer Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. ... 07/05/07 - 20070154487 - Compositions and methods for modulation of rorgammat functions The present invention relates to expression of RORγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of IL17 producing cells. Furthermore, the invention relates to methods and agents that may ... 07/05/07 - 20070154486 - Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a HLH2 haemocyanin polypeptide and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct further can comprise a nucleic acid sequence that codes for an ... 06/28/07 - 20070148184 - Survivin-derived peptides and use thereof MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-γ-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in ... 06/21/07 - 20070141073 - Antigen-drug vehicle enabling transmucosal and transdermal administration, and method of inducing mucosal immunity and mucosal vaccine and dds using the same Disclosed are an antigen-drug vehicle (AD vehicle) exerting a function of inducing the preferential and selective production of an antigen-specific secretory IgA antibody, local immunity or mucosal immunity; a method of inducing mucosal immunity, a mucosal vaccine and a preventive or a remedy for allergy using the above AD vehicle; ... 06/21/07 - 20070141072 - Use of multifunctional transcription factor yin-yang-1 and variants thereof for treating illnesses, especially type 1 diabetes The present invention relates to the influence of the activity and/or the expression of the multifunctional transcription factor Yin Yang 1 (YY1), and of variants thereof, for the treatment of many different illnesses. The invention especially relates to a mutated nucleic acid sequence which encodes a variant of the human ... 06/14/07 - 20070134261 - Effectors of innate immunity The present invention provides a method of identifying agents that enhance innate immunity in a subject. The invention further provides a method of selectively supressing sepsis by suppressing expression of a proinflammatory gene while maintaining expression of an anti-inflammatory gene. Also provided are methods of identifying a polynucleotide or pattern ... 06/14/07 - 20070134260 - Use of clusterin for the treatment and/or prevention of peripheral neurological diseases The invention relates to the use of clusterin, or of an agonist of clusterin activity, for treatment or prevention of peripheral neurological diseases, The invention further relates to the use of a combination of clusterin and heparin, for treatment or prevention of peripheral neurological diseases. ... 06/07/07 - 20070128209 - Vaccine based method for protection against hiv infection A vaccine based method for the prevention of HIV infection, suitable for HIV negative persons, is described. The method comprises the combination of (a) an immunization with material containing foreign MHC class II and (b) receiving a preparation containing the same foreign MHC class II, for example (i) taken orally ... 06/07/07 - 20070128208 - Method for the treatment of airway diseases A method for the treatment of allergic airway diseases in mammals related to Pythiosis insidiosum is described. The method relies upon an immunotherapeutic product of pythium proteins as antigens. The method is particularly useful in equine cicatrix. ... 06/07/07 - 20070128207 - Method of selecting wt1 vaccine adaptive patient A method of selecting patients highly responsive to WT1 vaccine and a therapeutic method for treating cancer involving said method of selection are provided, which method of selecting patients highly responsive to WT1 vaccine comprises: (a) isolating a biological sample containing CTL precursor cells from a test subject; (b) measuring ... 05/31/07 - 20070122423 - Derp1 and proderp1 allergen derivatives The present invention provides a novel treatment for allergy comprising the provision of a recombinant DerP1/ProDerP1 allergen derivative with hypoallergenic activity. Pharmaceutical compositions comprising said mutant allergens which stimulate a Th1-type immune response in allergic or naive individuals thereby reducing the potential for an allergic response upon contact with the ... 05/31/07 - 20070122422 - Sodium-independent small neutral amino acid transporter transporting l- and d- amino acids Novel sodium-independent small neutral amino acid transporters which transport L- and D-amino acids. A protein comprising the amino acid sequence represented by SEQ ID NO:1 or 4 or an amino acid derived therefrom by deletion, substitution or addition of one or more amino acids and being capable of sodium-independently transporting ... 05/31/07 - 20070122421 - Innate immune system-directed vaccines The present invention provides novel vaccines, methods for the production of such vaccines and methods of using such vaccines. The novel vaccines of the present invention combine both of the signals necessary to activate native T-cells—a specific antigen and the co-stimulatory signal—leading to a robust and specific T-cell immune response. ... 05/31/07 - 20070122420 - Protein antigens useful for cancer therapy and vaccination PstS1 protein or fragments thereof are highly immunogenic protein antigens for vaccination and immunotherapy of cancer in humans and animals. A wild-type or a recombinant mycobacterial PstS1 protein are used for the preparation of a vaccine or therapeutical composition for the treatment of cancer, in particular for the treatment of ... 05/31/07 - 20070122419 - Methods and compositions for treating atherosclerosis During the progression of atherosclerosis, autoantibodies are induced to epitopes of oxidized low-density lipoprotein (OxLDL), and active immunization of hypercholesterolemic mice with OxLDL ameliorates athero-genesis. The present studies have identified anti-OXLDL autoantibodies that share complete genetic and structural identity with antibodies produced by anti-phosphorylcholine B-cell clone, T15. ... 05/24/07 - 20070116710 - Methods of treating hemolytic anemia Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody. ... 05/17/07 - 20070110760 - Methods and compositions targeting viral and cellular itam motifs, and use of same in identifying compounds with therapeutic activity This invention provides methods of treating, reducing the incidence of, and inhibiting metastasis formation of carcinomas, sarcomas, Epstein-Barr virus-induced malignancies, B cell proliferative disorders, and mast cell activation disorders, comprising administering to a subject a compound that inhibits an interaction of a first protein and an immunoreceptor tyrosine-based activation motif ... 05/10/07 - 20070104725 - Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis The present invention relates to the use of fibronectin, tenascin, collagens type I, III, VI and/or VIII modified by aldehyde or by glycosylation in ELISA for detection of antibodies in plasma and serum to diagnose atherosclerosis as well as the use of induction of tolerance and active as well as ... 05/03/07 - 20070098736 - Injection vehicle for polymer-based formulations The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles ... 05/03/07 - 20070098735 - Methods for the elimination of pathogens and other particulate agents Disclosed herein are methods of treating infections, wounds, and exposure to particulate agents, comprising administering a heat shock protein (HSP) such as HSP70. The HSP may be uncomplexed to an antigenic peptide. Uncomplexed HSPs have been shown to activate phagocytosis by macrophages, and are thus particularly useful for the rapid ... 04/26/07 - 20070092532 - Arthritis vaccines and methods Vaccine compositions for preventing the onset or induction of arthritis in a subject susceptible to developing arthritis, comprising an arthritic protective peptide comprising the amino acid sequence of SEQ ID NO: 1. In various embodiments, the anti-arthritic peptide is admixed with an adjuvant in a pharmaceutically acceptable carrier. Methods include ... 04/26/07 - 20070092531 - Compositions for immunotherapy and uses thereof The present invention relates to an immunogenic composition comprising a conjugate between an antigen and an oxidized mannan comprising mannose units and aldehyde groups, and a pharmaceutically acceptable carrier. ... 04/26/07 - 20070092530 - Antibodies as t cell receptor mimics, methods of production and uses thereof The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such ... 04/26/07 - 20070092529 - Compositions and methods for diagnosing and treating cancers Compositions and methods for diagnosing, monitoring, or treating cancers. Genes encoding transmembrane proteins that are over-expressed in colon, lung, breast, prostate, liver, stomach, esophagus, or kidney cancer tissues are identified. These transmembrane genes can be used as biological markers for the detection or diagnosis of cancers. These genes can also ... 04/26/07 - 20070092528 - Superantigen fusion protein for anti-cancer therapy and methods for the production thereof The present invention provides a fusion protein, comprising: a) a ligand that stimulates cancer cell growth and corresponds to receptors overexpressed by cancer cells, or a screened peptide that is affinitive to or antagonist to cancer cell receptors, or a peptide that directly interacts with cancer cell surface; b) a ... 04/26/07 - 20070092527 - Proton-sensing g-protein coupled receptors and dna sequences thereof This invention relates to the newly identified utility of certain G protein-coupled receptors (GPCRs), in particular to OGR1, GPR4 and TDAG8 (TDAG8 is also named GPR65) polypeptides, and polynucleotides encoding such GPCR polypeptides, to their use in diagnosis and to methods of identifying compounds that are agonists or antagonists to ... 04/05/07 - 20070077255 - Isolation and characterization of a cdna clone encoding one ige-binding fragment of penicillium brevicompactum Pen b 26 was isolated as an allergen of Penicillium brevicompactum, which is known to be one of the major source of indoor fungal allergies. Pen b 26 was isolated and cloned into Escherichia coli as an N-terminus his-tagged fusion protein, which had a calculated molecular weight of 14.9 kDa ... 04/05/07 - 20070077254 - Targeting the histone code as a bacterial strategy for selectively modulating gene expression The ospF gene of Shigella flexneri encodes a phosphatase, which is a member of a new class of phosphatases. The OspF phosphatase inhibits the activity of several proteins either by direct protein modification or transcription downregulation. These proteins include MAP kinase, IL-8, CCL20, IL-12, AP1, CREB, RPA p32, and BCL2 ... 03/29/07 - 20070071767 - Tumor antigen Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises ... 03/29/07 - 20070071766 - Compositions comprising fungal immunomodulatory protein and use thereof This present invention relates to fungal immunomodulatory proteins, compositions and method for use in immunotherapy, treating or preventing cancer due to metastasis or suppression of telomerase activity by down-regulation of the telomerase catalytic subunit (hTERT), activating natural killer cells, macrophage or increasing serum antibody. The present invention also relates to ... 03/22/07 - 20070065454 - Liposomal vaccine The invention provides liposomal vehicles for encapsulating relatively high levels of water-soluble substances including immunogens directed against gastrin and gonadotropin releasing hormone. The liposome encapsulating large amounts of immunogens can be injected parentally to induce effective immune responses without exhibiting significant adverse tissue reactogenicity. ... 03/15/07 - 20070059319 - Methods of screening for immuno-adjuvants and vaccines comprising anti-microtubule immuno-adjuvants A method of screening for agents that stimulate the innate immune system in mammals employs markers that respond to Toll-like receptor binding. Agents identified in the assay boost both innate and adaptive immune responses, when administered alone or in combination with vaccines. ... 03/08/07 - 20070053921 - Nucleic acid and corresponding protein entitled 24p4c12 useful in treatment and detection of cancer A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The ... 03/08/07 - 20070053920 - Nematode polypeptide adjuvant The invention relates to a set of novel immunological adjuvants based upon so called “polyladder” proteins of nematode worms. These proteins are typified by repeating units separated by a protease cleavage motif of RX(K/R)R or RXFR where R is ariginine, X is any amino acid, K is lysine and F ... 03/01/07 - 20070048328 - Allergy prevention method or treatment method, diet and oral drug The invention provides an allergy prevention method or treatment method, diets and oral drugs enabling prevention/treatment of allergic symptoms without trouble such as systemic adverse reaction, immune deficiency and the like caused by transdermal/intravenous administration of TGF-β. The allergy prevention method or treatment method is to orally administer 100 μg/kg ... 02/22/07 - 20070041987 - Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development An isolated fusion protein is provided which is a conjugate of a therapeutic polypeptide and an albumin fragment, such as a fragment including an individual domain or subdomain of albumin, or a polymer of albumin (e.g., dimers, trimers, etc.) and which is used to optimize the half-life of that therapeutic ... 02/15/07 - 20070036813 - Vegf-related protein A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity ... 02/15/07 - 20070036812 - Hla-a24 binding cancer antigen peptide derived from livin The present invention provides a partial peptide consisting of 8-11 contiguous amino acids in the amino acid sequence of livin set forth in SEQ ID NO: 1, which binds to HLA-A24 antigen and is recognized by cytotoxic T cells (CTLs), a polynucleotide encoding the peptide, and cancer vaccine comprising the ... 02/15/07 - 20070036811 - Therapeutic cancer vaccine The present invention relates to polypeptide fragments capable of raising a specific T-cell response, wherein said fragment comprises a peptide consisting of at least 9 consecutive amino acid residues of ML-IAP as well as to said fragments for use as medicaments. The invention furthermore relates to use of said polypeptide ... 02/15/07 - 20070036810 - Cyclic amp response element activator proteins and uses related thereto The invention discloses newly identified cyclic AMP response element activator proteins (CREAP proteins). It is contemplated herein that said proteins are suitable drug targets for the development of new therapeutics to prevent, treat or ameliorate pathological conditions related to abnormal activation of CRE-dependent gene expression or abnormal activation of chemokines. ... 02/15/07 - 20070036809 - Tolerance-induced targeted antibody production The present invention provides methods for directing the immune response of an animal towards immunologically weak or rare antigens such as tumor antigens. The methods combine subtractive immunization with hyperimmunization and result in the controlled or directed production of target-specific antibodies, helper T cells (CD4+-T lymphocytes) and cytotoxic T cells ... 02/15/07 - 20070036808 - Cancer antigen peptide formulations Cancer antigen peptides derived from WT1 which have an in vivo efficacy, particularly a clinical usefulness, and cancer vaccines as dosage forms suitable for said cancer antigen peptides, are provided. The invention relates to water-in-oil emulsions which comprise as an effective ingredient either one or both of peptides selected from ... 02/08/07 - 20070031445 - Compositions and methods for enhancing immune responses mediated by antigen-presenting cells Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen, e.g. tumor associated antigens, bacterial or viral antigens. The ligand and the immunogen are linked via a cleavable linker such as a protease-sensitive oligopeptide, to facilitate processing of the adjuvant by the antigen presenting cell. Methods ... 02/08/07 - 20070031444 - Compounds targeted to cellular locations A soluble derivative of a soluble polypeptide, which comprises two or more heterologous membrane binding elements with low membrane affinity covalently associated with the polypeptide, the elements being soluble in aqueous solution, and the elements being capable of interacting, independently and with themodynamic additivity, with components of cellular or artificial ... 02/08/07 - 20070031443 - Methods for treating or preventing skin disorders using cd2-binding agents Methods for treating or preventing an epidermal or dermal disorder, e.g., psoriasis, using a CD2-binding agent, e.g., an inhibitor of the CD2/LFA-3 interaction (e.g., an LFA-3/IgG fusion polypeptide), in combination with an auxiliary agent, e.g., UVB irradiation, are disclosed. ... 02/08/07 - 20070031442 - Method and compositions for boosting immune response An antigen presenting molecule is capable of increasing sensitivity of a cytotoxic T lymphocyte to an antigen by interaction with a T cell receptor and CD8 coreceptor thereon, when the antigen presentation molecule displays an increased avidity for the CD8, compared to the molecule encoded by SEQ ID NO. 1 ... 02/01/07 - 20070026008 - Compositions and methods for wt1 specific immunotherapy Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that ... 02/01/07 - 20070026007 - Purposeful movement of human migratory cells away from an agent source This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of cells of hematopoietic, neural, epithelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, ... 01/25/07 - 20070020284 - Ob fusion protein compositions and methods The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or ... 01/25/07 - 20070020283 - Interferon-gamma antagonists and therapeutic uses thereof Polypeptides and multimeric polypeptides capable of binding interferon γ which are useful therapeutically in methods of treating interferon γ-related conditions or diseases. ... 01/18/07 - 20070014809 - B cell activation and polypeptides having cd14 activity A novel protein purified from bovine colostral whey and isolated nucleotide sequences encoding the protein is identified. The isolated bovine protein is termed Bovine Lactation Associated Immunotropic (Bo-LAIT) protein. The human homologue of Bo-LAIT protein, Hu-LAIT protein, is also described. A method of activating B cells, and particularly of activating ... 01/18/07 - 20070014808 - Polypeptide The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use ... 01/18/07 - 20070014807 - Multiplex vaccine The present invention provides antigen complexes comprising 15 or more, in some instances 15 to 100 or more, different antigens and/or compositions comprising the antigen complexes where the composition comprises 15 or more, in some instances 15 to 100 or more, different antigens. The invention also provides to methods of ... 01/11/07 - 20070009544 - Anti-allergic complex molecules The present invention discloses novel therapeutic complex molecules, and in particular, peptidic or peptidomimetic molecules, comprising a first part which is competent for cell penetration and a second part which is able to reduce or abolish mast cell degranulation, in particular to reduce or abolish allergy mediators, including histamine secretion ... 01/11/07 - 20070009543 - Protein involved in ovarian cancer The present invention relates to new uses of CDCP1 in the diagnosis, screening, treatment and prophylaxis of ovarian cancer. The invention also provides compositions comprising CDCP1, including vaccines, antibodies that are immunospecific for CDCPI and agents which interact with or modulate the expression or activity of CDCP1 or which modulate ... 12/28/06 - 20060292166 - Vaccine composition comprising flt3-ligand Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T ... 12/28/06 - 20060292165 - Compositions and methods for enhancement of major histocompatibility complex class i restricted antigen presentation Compositions and methods for eliciting an in vivo cytotoxic lymphocyte (CTL) response against a modified soluble protein antigen are disclosed. The modified soluble protein antigen comprises an added peptidic sequence which facilitates entry of the modified antigen into antigen presenting cells (APC). ... 12/28/06 - 20060292164 - Method for preventing rejection of transplanted tissue Methods of preventing rejection of transplanted tissue. Recipient alloactivated regulatory T cells generated ex vivo are introduced into the recipient before transplantation. Donor antigen is introduced into the recipient after transplantation to boost recipient regulatory T cells. ... 12/21/06 - 20060286117 - Neuronally expressed stem cell factor modulates angiogenesis and neural stem cell migration to areas of brain injury The present invention relates to methods of promoting or inhibiting angiogenesis in humans comprising administering to a human in need thereof an effective amount of Stem Cell Factor or a modulator of Stem Cell Factor or an agonist or antagonist of c-Kit and methods of inducing migration of a neural ... 12/21/06 - 20060286116 - Methods and compositions for treating b cell cancer Disclosed are methods for killing or retarding the growth of a B cell cancer cell, by contacting the cell with a FRIL family member molecule. Also disclosed are methods for determining if a B cell cancer is sensitive to a FRIL family member molecule, or if a B cell cancer ... 12/21/06 - 20060286115 - Preventive cancer vaccine based on brother of regulator of imprinted sites molecule Polynucleotides encoding a nonfunctional mutant form of the Brother of Regulator of Imprinted Sites (BORIS) molecule, nonfunctional mutated BORIS protein, polypeptide or peptide and modified protein forms of BORIS are described. These molecules are used as a therapeutic vaccine against cancer. ... 12/21/06 - 20060286114 - Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof Synthetic polynucleotides encoding rhesus monkey carcinoembryonic antigen (CEA) are provided, the synthetic polynucleotides being condon-optimized for expression in a human cellular environment. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein ... 12/07/06 - 20060275314 - Transmembrane protein differentially expressed in cancer The invention provides a transmembrane protein that is differentially expressed in neoplastic disorders. It also provides for the use of the protein, a cDNA encoding the protein, and antibodies that specifically bind the protein in various methods to diagnose, stage, treat, or monitor the treatment of a neoplastic disorder. ... 12/07/06 - 20060275313 - Therapeutic and diagnostic agents The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides molecules having structural features characteristic of immunoregulatory signaling (IRS) molecules and which are expressed by cells of heaematopoietic lineages such as, in particular, leukocytes. The molecules of the present invention find broad application inter ... 11/30/06 - 20060269561 - Compositions and methods for treatment of non-hodgkins lymphoma The present invention provides recombinant peptides comprising a B cell receptor (BCR) or a fragment thereof, nucleotide molecules encoding same, and vaccines and vectors comprising same; and methods of treating, inducing an immune response against, inducing a regression of, and suppressing a formation of a lymphoma, comprising administering same. The ... 11/23/06 - 20060263383 - Prognostic indicator A prognostic indicator for metastasis comprises an antibody directed against osteopontin. ... 11/23/06 - 20060263382 - Membrane-permeant peptide complexes for treatment of sepsis Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided. ... 11/23/06 - 20060263381 - Peptide epitopes common to antigens of the same multigene family The invention relates to the production of peptide epitopes common to a plurality of antigens of the same multigene family, said epitopes containing at least one common pentapeptide sequence preceded by three amino acids at the N-terminal end and optionally followed by one or two amino acids at the C-terminal ... 11/16/06 - 20060257420 - Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions x is a direct bond or linker for covalently bonding P1 and P2. ... 11/09/06 - 20060251669 - Compositions and methods for treating malaria with cupredoxin and cytochrome The present invention relates to cupredoxin and cytochrome and their use, separately or together, to inhibit the spread of parasitemia in mammalian red blood cells and other tissues infected by the malaria parasite, and in particular the parasitemia of human red blood cells by P. falciparum. The invention provides isolated ... 11/09/06 - 20060251668 - Tumor-specific recognition molecules The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases. ... 11/09/06 - 20060251667 - Recombinant nucleic acid useful for inducing protective immune response against allergens The invention provides a recombinant nucleic acid useful for inducing a protective immune response against an allergen. The recombinant nucleic acid encodes an allergen and a signal peptide that mediates the translocation of the allergen to endoplasmic reticulum and preferably also encodes a second signal peptide that targets the gene ... 11/09/06 - 20060251666 - Cancer antigens and utilization thereof An object of the present invention to provide: a human pancreatic cancer antigen and/or a human colon cancer antigen that can be applied to the diagnosis and/or treatment of various types of cancers or tumors including pancreatic cancer and colon cancer as representative examples; a gene encoding the same; an ... 11/09/06 - 20060251665 - Vaccines The present invention relates to the novel nucleic acid constructs, useful in nucleic acid vaccination protocols for the treatment and prophylaxis of MUC-1 expressing tumors. In particular, the nucleic acid is DNA and the DNA constructs comprise a gene encoding a MUC-1 derivative having less than 10 perfect repeat units. ... 10/26/06 - 20060240033 - Use of allogenic or syngenic major histocompatibility complex (mhc) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease The present invention is directed to the discovery that allogenic or syngenic adjuvant stimulation can cause local inflammation which increases the antigen presentation capability of cells in the vicinity of adjuvant stimulation. By discovering this phenomenon, the present invention provides a novel method for augmenting the immunogencity of an antigen ... 10/26/06 - 20060240032 - Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases A composition and method for treating an autoimmune condition are disclosed. The composition includes of an immunomodulating compound composed of a central amino acid core having a plurality of chemical attachment groups, and a plurality of antigenic peptides which are (i) associated with an auto-immune disorder and (ii) attached to ... 10/26/06 - 20060240031 - T cell receptor cdr3 sequences and methods for detection The present invention relates generally to the field of treating autoimmune diseases, such as multiple sclerosis (MS), rheumatoid arthritis (RA) and others. Methods of treating and monitoring an autoimmune disease by utilizing T-cell receptors peptides are disclosed. Nucleic acid and peptide sequences of T-cell receptors found in a population of ... 10/19/06 - 20060233819 - Inhibition of t cell activation by butyrophilin 4 or b7-l1 The invention provides methods for modulating an immune response comprising contacting an immune cell with an agent that modulates BTF4 or B7-L1 mediated signaling. BTF4 or B7-L1 mediated signaling may either be increased, to thereby downregulate the immune response, or alternatively may be decreased, to upregulate the immune response. Modulation ... 10/19/06 - 20060233818 - Organic compounds Dendritic cell (DC) genes and polypeptides and their function in the identification of compounds which are (ant)agonists; and (ant)agonists to DC polypeptides. ... 10/19/06 - 20060233817 - Peptide-based immunization therapy for treatment of atherosclerosis The present invention relates to a fragment of apolipoprotein B, for immunization for prophylactic or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, in particular myocardial infarction or stroke, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing ischemic ... 10/12/06 - 20060228371 - Immunological control of beta-amyloid levels in vivo An antibody and vectorized antibody, capable of crossing the blood brain barrier, which catalyze hydrolysis of β-amyloid at a predetermined amide linkage are described. The antibody preferentially binds a transition state analog which mimics the transition state adopted by β-amyloid during hydrolysis. Also described are methods for sequestering free β-amyloid ... 10/12/06 - 20060228370 - 7a5/prognostin and use thereof for the diagnostic and therapy of tumors The present invention refers to the nucleic acid sequence encoding for the polypeptide of 7a5/Prognostin and to its uses, in particular for the tumour diagnostics and tumour therapy of metastasising tumours. ... 10/05/06 - 20060222656 - Mage-a3/hpv 16 peptide vaccines for head and neck cancer The present invention relates to Trojan antigens, and immunogenic compositions comprising the Trojan antigens. The present invention also relates to methods of generating an immune response in a subject using the Trojan antigens or immunogenic compositions. The present invention further relates to methods of treating squamous cell carcinoma of the ... 09/28/06 - 20060216303 - Processes and products with modified antibodies of human milk fat globule specificity An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions ... 09/28/06 - 20060216302 - Immunological markers Compounds, compositions and methods for identifying human or other animals having a particular characteristic, by administration of an antigenic marker that elicits a unique antigenic response. Compositions comprise: (a) an antigenic marker; and (b) a pharmaceutically-acceptable carrier wherein said marker does not elicit a vaccination immune response. In a preferred ... 09/28/06 - 20060216301 - Kdr peptides and vaccines containing the same The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO: 2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO: 29, 30, 33, 34, 40, or 46; and peptides with cytotoxic ... 09/21/06 - 20060210577 - Rtvp-glipr-like compositions and methods for the detection, treatment and prevention of prostate cancer The invention is directed to purified and isolated novel RGL2 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ... 09/21/06 - 20060210576 - Method for treating or preventing metastasis of colorectal cancers Disclosed are methods of identifying agents for treating metastatic lesions of colorectal cancer. Also disclosed are methods for treating metastatic lesions of colorectal cancer and preventing metastasis of colorectal cancer. ... 09/21/06 - 20060210575 - Cytotoxic protein and utilization thereof This invention provides a cytotoxic protein (M toxin) produced by Helicobacter pylori, a partial peptide, and an antitumor agent containing the cytotoxic protein. The protein is obtained by culturing a transformant which is transformed with a recombination vector containing DNA coding the cytotoxin protein. This invention provides further the use ... 09/14/06 - 20060204512 - Polypeptide compounds for inhibiting angiogenesis and tumor growth In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases. ... 09/14/06 - 20060204511 - Use of recombinant or synthetic gelatin as stabiliser in vaccines The invention relates to methods for preparing vaccine and pharmaceutical compositions comprising recombinant or synthetic gelatin as a stabiliser and to the vaccine and pharmaceutical formulations themselves, as prepared by these methods. ... 09/07/06 - 20060198851 - Humanized abeta antibodies for use in improving cognition The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (Aβ). Preferred agents include antibodies, e.g., humanized antibodies specific for Aβ. ... 08/31/06 - 20060193871 - Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood flow. A method of treating visceral pain or visceral hypersensitivity in a human subject is also described. A method for prolonging ... 08/24/06 - 20060188513 - Novel inhibin-related multiple antigenic peptide compositions that enhance production performance in avians The present invention provides novel compositions of matter comprising MAP compositions comprising at least 2 inhibin-related peptides linked to a backbone. These compositions are immunogenic and enhance production performance when administered together with an acceptable carrier to animals, especially avians. ... 08/24/06 - 20060188512 - Active immunization to generate antibodies to solble a-beta The invention provides methods useful for effecting prophylaxis or treatment of Alzheimer's disease. Such methods entail administering A-beta fragments from a central or C-terminal regions of A-beta. Such fragments can induce a polyclonal mixture of antibodies that specifically bind to soluble A-beta without binding to plaques. The antibodies can inhibit ... 08/17/06 - 20060182755 - Novel composition and methods for the treatment of psoriasis The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of psoriasis. ... 08/10/06 - 20060177461 - Stress proteins and uses therefor The present invention relates to stress proteins and methods of modulating an individual's immune response. In particular, it relates to the use of such stress proteins in immune therapy and prophylaxis, which results in an induction or enhancement of an individual's immune response and as an immunotherapeutic agent which results ... 08/10/06 - 20060177460 - Stress proteins and uses therefor The present invention relates to stress proteins and methods of modulating an individual's immune response. In particular, it relates to the use of such stress proteins in immune therapy and prophylaxis, which results in an induction or enhancement of an individual's immune response and as an immunotherapeutic agent which results ... 08/03/06 - 20060171954 - Antigen specific activated t-lymphocytes, detection and use The invention concerns autoreactive peptides, peptide-MHC complexes, T cell subpopulations that react thereto as well as diagnostic and therapeutic applications of these compounds. ... 08/03/06 - 20060171953 - Tumour-specific animal proteins CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal cancers, autoimmune diseases, and related conditions. ... 07/27/06 - 20060165712 - Catalytically active peptides A catalytically active peptide comprising an imidazole function in position i flanked by at least one functional group to be amidated in position i+3+4k, where k is an integer equal to or higher than −1 or in position i−4−4n, wherein n is an integer equal to or higher than 0, ... 07/27/06 - 20060165711 - Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes Embodiments relate to methods and compositions for eliciting, enhancing, and sustaining immune responses, preferably multivalent responses, preferably against MHC class I-restricted epitopes. The methods and compositions can be used for prophylactic or therapeutic purposes. ... 07/27/06 - 20060165710 - Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes The present invention relates to the use of alpha (2) macroglobulin complexes isolated from the serum of a mammal. The invention also relates to methods for making such complexes and compositions comprising alpha (2) macroglobulin complexes, isolated from the serum of a mammal, wherein such compositions are used in methods ... 07/27/06 - 20060165709 - Cancer vaccines containing epitopes of oncofetal antigen Disclosed are fragments of oncofetal antigen, otherwise known as immature laminin receptor protein that specifically stimulate one T cell subclass. The fragments may be formulated into compositions for potentiating T cell-mediated response in mammalian cancer patients. They also have therapeutic uses in vitro. ... 07/27/06 - 20060165708 - Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes A cancer vaccine comprising a cancer antigen which comprises, as an active ingredient, the product of a tumor suppressor gene WT1, a partial peptide or a modified version thereof, and a cationic liposome. ... 07/27/06 - 20060165707 - Substances The present invention provides a multimers of class I Major Histocompatibility Complexes (MHCs) having a modified P2-microglobulin whose binding to CD8 is inhibited. Such MHCs are capable of inhibiting CD8+ T cell response, particularly by inducing apoptosis or anergy of the T cell. The invention also provides nucleic acids encoding ... 07/20/06 - 20060159694 - Combinations of tumor-associated antigens in compositions for various types of cancers Disclosed herein are methods and compositions for inducing an immune response against various combinations of tumor-associated antigens, which can promote effective immunologic intervention in pathogenic processes. Embodiments of the invention disclosed herein are directed to the use of effective combinations of TuAAs for the immunotherapy of patients with various types ... 07/20/06 - 20060159693 - Idiotypic vaccine The present invention relates to idiotypic vaccine compositions for use in inducing immunity to p53. The invention preferably relates to a vaccine composition comprising a pharmaceutically acceptable carrier and at least one peptide, wherein the at least one peptide is selected from the group consisting of X1-LLQALKH-Y1, X2-FIRKAYGAATAYAASKKG-Y2 and X3-MQGLQTPYT-Y3 ... 07/20/06 - 20060159692 - Transcriptional factor inducing apoptosis in cancer cell A new method for treating cancer by inducing apoptosis exclusively in cancer cells and killing them is provided. The present invention relates to a transcriptional factor, comprising p53 or a mutated type p53, wherein one or more amino acids are deleted, substituted or added with respect to the amino sequence ... 07/20/06 - 20060159691 - Ptprk immunogenic peptide An immunogenic peptide isolated from PTPRK protein represents a novel HLA II restricted epitope recognized by CD4+T cells and is used in cancer immunotherapy or diagnosis. ... 07/13/06 - 20060153861 - Bcr-abl imatinib resistance-associated peptides and methods of use thereof The present invention is directed to immunogenic peptides, compositions and vaccines comprising same, and methods of use thereof for treating, inhibiting or reducing the incidence of a cancer associated with an activated kinase, and methods of generating a heteroclitic immune response against, or cytotoxic T cells specifically recognizing cancer cells ... 07/13/06 - 20060153860 - Novel antigen-binding polypeptides and their uses Novel antigen-binding polypeptides (ABP) and uses thereof are provided. ... 07/06/06 - 20060147460 - Anticancer vaccine and diagnostic methods and reagents The invention provides a method for vaccinating a patient against a malignancy comprising introducing a protein or peptide comprising of all or an immunogenic fragment of a cyclin protein into the patient. The invention further provides a method of identifying tumor antigens. ... 07/06/06 - 20060147459 - Epitope composition for sublingual, buccal or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin In the case of a module (1) for a data carrier (11) designed for contactless communication, the module (1) has a chip (3) with at least two pairs (20, 21) of chip connection contacts (4, 5, 6, 7) and with at least two pairs (22, 23) of module connecting plates ... 07/06/06 - 20060147458 - Vaccines Novel MUC-1 DNA constructs are provided that have reduced homology to native MUC-1. Pharmaceutical compositions containing such MUC-1 constructs are provided. ... 06/29/06 - 20060140970 - Proteic binding partners of tctp and methods of modulating tumor reversion or cell apoptosis This invention encompasses proteic binding partners of Translationally Controlled Tumor Protein (TCTP), which can modulate tumor reversion or cell apoptosis. Methods of screening for compounds useful for treating, preventing or managing cancer, an inflammatory disorder, or a neurodegenerative disorder and use of these compounds are also encompassed. ... 06/29/06 - 20060140969 - Hypoallergenic polypeptides based on fish parvalbumin The present invention relates to non-naturally occurring polypeptides derived from fish allergens such as parvalbumin Cyp c 1.01 from carp. The polypeptides display reduced allergenic activity and are useful as allergy vaccines for treatment of sensitized allergic patients and for prophylactic vaccination. ... 06/29/06 - 20060140968 - Novel tumor antigen protein sart-3 and tumor antigen peptides thereof A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided. ... 06/29/06 - 20060140967 - Immunogenic peptides for the treatment of prostate and breast cancer Immunogenic T-cell receptor gamma Alternate Reading Frame Protein (TARP) polypeptides are disclosed herein. These immunogenic TARP polypeptides include nine consecutive amino acids of the amino acid sequence set forth as SEQ ID NO: 9 and do not comprise amino acids 1-26 or amino acids 38-58 of SEQ ID NO: 1. ... 06/29/06 - 20060140966 - Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins The present invention relates to complexes and fusion proteins comprising an acute phase protein and an antigenic molecule, for use in the treatment or prevention of a disease. The invention specifically provides for complexes comprising an acute phase protein noncovalently bound to, or alternatively crosslinked to, an antigenic molecule. The ... 06/29/06 - 20060140965 - Immunogenic compositions comprising a xenogenic prostate protein p501s The present invention relates to pharmaceutical/immunogenic compositions and methods for inducing an immune response against tumour-related antigens. More specifically, the invention relates to non-human prostate-specific antigens, more precisely to the non-human prostate-specific P501S, which can be used as xenogeneic antigen in prostate cancer vaccine therapy and as diagnostic agents for ... 06/22/06 - 20060134130 - Oral drug delivery compositions and methods The present invention relates to an oral drug delivery system, and in particular to modified amino acids and modified amino acid derivatives for use as a delivery system of sensitive agents such as bioactive peptides. The modified amino acids and derivatives can form non-covalent mixtures with active biological agents and ... 06/22/06 - 20060134129 - Synthetic hla binding peptide analogues and uses thereof The present invention is directed to immunogenic bcr-abl-based peptides, compositions and vaccines comprising same, and methods of use thereof for treating, inhibiting or reducing the incidence of a bcr-abl-expressing cancer, and methods of generating a heteroclitic immune response against, or cytotoxic T cells specifically recognizing bcr-abl-expressing cancer cells. ... 06/22/06 - 20060134128 - Novel adaptor protein binding to mammalian toll-like receptor 3, and gene thereof A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors, ... 06/22/06 - 20060134127 - Antiallergic agent It is intended to provide an anti-allergic agent, which efficaciously relieves symptoms accompanying an allergic disease without causing any serious side effect. This object is achieved by providing an anti-allergic agent which contains, as an effective ingredient, proteins collected from royal jelly or purified royal jelly, or royal jelly or ... 06/22/06 - 20060134126 - Peptide constructs for treating disease This invention relates to peptides directing a CD4 related T helper cell response wherein the peptides may be used as an adjuvant provided with an antigen or as an immunomodulatory agent without an antigen and compositions comprising modification of a fifteen-mer peptide sequence from the MHC IIβ chain at positions ... 06/15/06 - 20060127410 - Naturally processed measles virus peptides eluted from class ii hla molecules A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more ... 06/15/06 - 20060127409 - Bcr-abl vaccines and methods of use thereof This invention provides vaccine comprising immunogenic bcr-abl peptides and methods of treating, inhibiting the progression of, reducing the incidence of, and breaking a T cell tolerance of a subject to a bcr-abl-associated cancer. ... 06/15/06 - 20060127408 - Cancer immunotherapy The invention relates to the use of polycomb group proteins as a tumour-associated antigens. Polycomb group proteins are highly involved in body architecture development, haematopoiesis and cell cycle control. Aberrant expression of polycomb proteins has been linked with haematological malignancies, mainly lymphomas. This invention relates to the use of these ... 06/08/06 - 20060121047 - Use of hmgb polypetides for increasing immune responses The present invention features polypeptides comprising an HMGB B box or a functional variant thereof that are useful for stimulating or increasing an immune response in an individual. Such polypeptides can be used in vaccine formulations and in cancer therapies. ... 05/25/06 - 20060110400 - Immunogenic conjugates The invention relates to an immunogenic conjugate comprising at least one vascular endothelial growth factor (VEGF) peptide moiety coupled to a carrier. ... 05/11/06 - 20060099218 - Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity The present invention relates to methods for enhancing exogenous epitope display on an MHC class I molecule through inhibition of TAP activity. Mammalian cell-infecting virus vectors encoding both a TAP inhibitory factor and an epitope-linked-β2m were constructed and introduced into mammalian cells. The present inventors succeeded in displaying on the ... 05/04/06 - 20060093615 - Tumor antigen based on products of the tumor suppressor gent wt1 A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising ... 05/04/06 - 20060093614 - Platelet glycoprotein ib alpha fusion polypeptides and methods of use thereof The present invention provides compositions and methods for treating or preventing vascular-associated disorders. ... 05/04/06 - 20060093613 - Soluble t cell receptor The present invention relates to a recombinant soluble T cell receptor. The T cell receptor (TCR) is refolded and comprises a recombinant TCR α or γ chain extracellular domain having a first heterologous C-terminal dimerization peptide; and a recombinant TCR β or δ chain extracellular domain having a second C-terminal ... 05/04/06 - 20060093612 - Use of heat shock proteins to enhance efficacy of antibody therapeutics The present invention relates to methods and pharmaceutical compositions useful for the prevention and treatment of any disease wherein the treatment of such disease would be improved by an enhanced immune response, such as infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), or neurodegenerative or amyloid diseases. In particular, ... 04/27/06 - 20060088544 - Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions Peptide constructs including a first peptide segment which includes an amino acid sequence associated with autoimmune disease, asthma, allergy or xeno- or allograft transplantation rejections bonded directly or via a linker or spacer to a second peptide which binds to T cells and which will redirect the immune response from ... 04/27/06 - 20060088543 - Use of passive myostatin immunization A method to alter the phenotype of animals, e.g., avians, which employs passive and active immunization is provided. ... 04/27/06 - 20060088542 - Imidazoquinoline adjuvants for vaccines The invention relates to the fields of vaccines, vaccine adjuvants, molecular biology and immunology, and generally relates to adjuvants and nucleic acid immunization techniques. More specifically, the invention relates to certain adjuvant compositions, and to vaccine and/or nucleic acid immunization strategies employing such compositions. ... 04/20/06 - 20060083751 - Therapeutic agents A method for treating diabetes in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 (GM-1) associated activity in an amount effect to treat the disease; wherein the agent, when in vivo, has an effect ... 04/20/06 - 20060083750 - Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing disseminated candidiasis. The method includes administering an immunogenic amount of a ... 04/13/06 - 20060078564 - Family of immunoregulators designated leukocyte immunoglobulin-like receptors (lir) A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences, processes for producing polypeptides of the LIR family, and antagonistic antibodies ... 04/13/06 - 20060078563 - Using heat shock proteins to increase immune response The present invention provides for a method of using heat shock proteins (HSPs) to amplify the immune response initiated by a vaccine. HSPs can be introduced into a subject before, concurrently, or after the administration of a vaccine. The HSPs can also be used to activate antigen presenting cells which ... 04/13/06 - 20060078562 - Rage fusion proteins and methods of use Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity ... 04/06/06 - 20060073159 - Human anti-cancer immunotherapy The present invention encompasses compositions and methods for activating, stimulating and isolating antigen-specific T cells. The present invention also relates to compositions of antigen-specific T cells and methods of their use in the treatment and prevention of cancer, infectious diseases, autoimmune diseases, immune disfunction related to aging, or any other ... 04/06/06 - 20060073158 - Methods and compositions comprising supramolecular constructs The present invention comprises novel compositions and methods for eliciting high immune responses, of great specifity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, P170 glycoprotein. The novel compositions of the invention comprise supramolecular ... 03/23/06 - 20060062799 - Sperm specific lysozyme-like proteins The present invention relates to two novel, testis-specific proteins (C19 and C23) that are lysozyme paralogues. The proteins are believed to play a role in capacitation of sperm and the fertilization of the ovum. Therefore these compounds make ideal targets for the design of contraceptive agents. The C19 and C23 ... 03/23/06 - 20060062798 - Vaccines The present invention provides nucleic acid constructs useful in nucleic acid vaccination for the treatment and prophylaxis of Muc-1 expressing tumours. The constructs are devoid of Muc-1 perfect repeats. ... 03/16/06 - 20060057154 - Compositions for inducing of immunotolerance Described are methods of treating allergic disorders and compositions for use therein. The methods comprise administering an allergen and one or more medicaments. These medicaments are compounds that inhibit the transcription of genes involved in the initiation of innate and specific immunity, thereby promoting the development of tolerance to these ... 03/16/06 - 20060057153 - Method and composition for the inhibition of mitosis A function for the human protein, Bsh3 was identified herein as being involved in mitosis. Thus, inhibitors of Bsh3 can be used for the treatment of cancer or other diseases marked by over-proliferation. Inhibitors of the yeast homolog (S. pombe Bsh3) can be used as anti-fungals. Alternatively, Bsh3 or Bsh3 ... 03/09/06 - 20060051359 - Recombinant immunotoxin and use in treating tumors Immunotoxins are disclosed that include a toxin, a variable region of a heavy chain of a monoclonal antibody that binds the antigen specifically bound by monoclonal antibody 8H9, and a variable region of a light chain of the monoclonal antibody that binds the antigen specifically bound by monoclonal antibody 8H9 ... 03/02/06 - 20060045884 - Vaccines for autoimmune and infectious disease The present invention provides HLA-restricted antigens as vaccines for treating or preventing autoimmune diseases or conditions, translpant rejection or vasculitis in a patient. In particular aspects, there is provided Pr3, a myeloid tissue-restricted protein and a HLA-A2.1-restricted self-peptide, PR1, derived from Pr3, which can be used to elicit PR1-specific CTLs. ... 03/02/06 - 20060045883 - Anti-cancer vaccines The present provides tumor-associated HLA-restricted antigens, and in particular HLA-A2 restricted antigens, as vaccines for treating or preventing cancers in a patient. In specific aspects, there is proteinase 3 peptides are provided. Such peptides can be used to elicit specific CTLs that preferentially attack myeloid leukemia based on overexpression of ... 02/23/06 - 20060039918 - Stress proteins and peptides and methods of use thereof Provided are HLA pan DR-binding peptides and methods of using such peptides to modulate, block, or inhibit immune responses to effect treatment of immune-mediated diseases and conditions, such as inflammatory and autoimmune diseases, cancer, and microbial infections. These peptides and methods are also useful diagnostically to screen peptide or peptide ... 02/16/06 - 20060034858 - Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is ... 02/16/06 - 20060034857 - Notch The present invention relates to the use of therapeutic compounds in the modification of T-cell, T-cell antigen presenting cell (APC) interactions and the interactions between pathogenic organisms and immunocompetent cells of a host. In particular it relates to the use of these compounds in the modulation of the interaction between ... 02/16/06 - 20060034856 - Epha2 antigen t epitopes The invention concerns peptides constituting T epitopes of EphA antigen, exhibited by MHC I. Said peptides are useful in particular in antitumoral immunotherapy. ... 02/16/06 - 20060034855 - Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AssPP epitope spanning the ss-secretase cleavage site of AssPP and a method for inducing an immune response against the ss-secretase cleavage site of ... 02/09/06 - 20060029611 - Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is ... 02/09/06 - 20060029610 - Grp94-based compositions and methods of use thereof Mini chaperones and methods of use thereof for the treatment of cancer and other disorders are provided. Also provided are tools to facilitate screening therapeutic agents which have selective binding affinity for GRP94. ... 02/02/06 - 20060024318 - Vaccination with immuno-isolated cells producing an immunomodulator The present invention relates to immuno-protected encapsulated cells producing an immunomodulator, for example GM-CSF (granulocyte-macrophage colony stimulating factor). The cells of the invention are particularly well adapted for providing an active adjuvant or immunomodulator, for example in the context of immunisation in humans and animals. These cells can be used ... 01/26/06 - 20060018918 - Production of stabilized conformational isomers of disease associated proteins The present invention includes compositions and methods for the development, isolation and characterization of vaccine that include one or more isolated and purified non-native, stabilized conformational protein isomer antigens. ... 01/26/06 - 20060018917 - Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers A novel gene (designated 158P1D7) and its encoded protein are described. While 158P1D7 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 158P1D7 provides a diagnostic and/or therapeutic target for cancers. The 158P1D7 gene or fragment thereof, ... 01/19/06 - 20060013823 - Anticancer agent The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor. ... 01/19/06 - 20060013822 - Utilization of mhc class ii binding motifs in immunization to produce immune, serum, monoclonal antibodies and vaccines This invention provides compositions and methods for raising humoral antibody responses. The compositions are peptides containing major histocompatibility Class 11 antigen binding motifs (ABM) either native or inserted into the peptide sequence. The ABM can be at the carboxy or amino terminus of the peptide and is shown to provide ... 01/12/06 - 20060008465 - Novel methods for therapeutic vaccination A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and ... 01/12/06 - 20060008464 - Histone conjugates and uses thereof A conjugate of a histone moiety covalently attached to a macromolecule-of-interest, in which the histone moiety is transportable through the cell membrane and importable into the cell nuclei, is disclosed. Further disclosed are chemical and recombinant methods of preparing such a conjugate, pharmaceutical compositions containing same and uses thereof for ... 01/05/06 - 20060002950 - Immunomodulatory protein derived from trypanosomes and uses thereof The present invention relates to the field of immunomodulation. More particularly, the present invention relates to the identification and isolation of a polypeptide derived from Trypanosomes that can be used to modulate the immune response in mammals. ... 01/05/06 - 20060002949 - Transcutaneous immunization without heterologous adjuvant Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response without the use of a heterologous adjuvant. Although perforation of intact skin is not required, superficial penetration ... 01/05/06 - 20060002948 - Allergen from house-dust mites The present invention relates to a novel allergen from house-dust mites, to polypeptides derived from said allergen and polynucleotides encoding the same. Furthermore, the invention provides antibodies directed against the allergen and to the use of the polypeptides, polynucleotides and/or antibodies in therapy and diagnosis of allergic disorders. ... 01/05/06 - 20060002947 - Ii-key/antigenic epitope hybrid peptide vaccines Disclosed is an antigen presentation enhancing hybrid polypeptide which includes three elements. The first element is an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity. The second element is a ... 01/05/06 - 20060002946 - Targeted immunogens The present invention provides reagents and methods for producing and utilizing targeted immunogens. In preferred embodiments, an immunogen is conjugated to an amino acid sequence that targets the immunogen to the MHC presentation pathway. Using the reagents and methods provided herein, immunization protocols may be enhanced resulting in increased immunity ... 12/29/05 - 20050287160 - Hla-a24 binding peptides of enhancer of zeste homolog 2 A cancer antigen peptide comprising an amino acid sequence shown in SEQ ID NO: 1 or 2, or a derivative thereof having the functionally equivalent property is provided. The provided cancer antigen peptide is a partial peptide derived from enhancer of zeste homolog 2, which is capable of binding to ... 12/29/05 - 20050287159 - Treatment methods for eotaxin mediated inflammatory conditons Immunogenic compositions which generate an active immune response in a subject comprising autoantibodies to eotaxim which neutralize its biological activity and treatment methods using such compositions. ... 12/29/05 - 20050287158 - The p65 subunit of nf-kb for the radiosensitization of cells The transcription factor NF-κB is activated in response to various stimuli including ionizing radiation. Disruption of NFκB activation by mutant forms of the NF-κB inhibitor IκB-α or by proteasome inhibitors enhances both sensitivity to radiation and radiation-induced apoptasis. The present invention shows that expression of a dominant negative fragment of ... 12/22/05 - 20050281836 - Synthetic vaccine for tick control This invention is related to the field of immunology of protein biotechnology and particularly to the construction of synthetic immunogens which result, where inoculated, in the production by cattle of an immune response capable of lesion to the ticks feeding on the inoculated bovines, reducing their number, their weight and ... 12/22/05 - 20050281835 - Surface protein of neisseria bacteria Present invention provides a monoclonal antibody binding to Neisseria bacteria and its target antigen Ag473, which include the sequences of its polynucleotide and its amino acid, wherein the Neisseria bacteria can be Neisseria meningitidis or Neisseria gonorrhoeae; and wherein Ag473 can be made into a vaccine or a diagnostic or ... 12/15/05 - 20050276813 - Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations Disclosed is the use of lipopeptides and lipoproteins as mucosal adjuvants for various vaccinations via mucous membranes, particularly intranasally. Said lipopeptides represent peptides or proteins substituted with 2,3-diacyloxy(2R)-propyl at the amino-terminal cystein of a peptide or protein, preferably S-(2,3-bispalmitoyloxy-(2R)-propyl)cysteinyl peptides derived from mycoplasmas. Said peptides are highly effective even in ... 12/08/05 - 20050271676 - Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human immunodeficiency virus (HIV) epitopes, and to develop epitope-based vaccines directed towards HIV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention ... 12/08/05 - 20050271675 - Methods for preparing immunogenic conjugates Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazino-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent ... 12/01/05 - 20050266014 - Tumor antigen based on products of the tumor suppressor gene wt1 A tumor antigen that comprises, as an active ingredient, a product of the Wilms' tumor suppressor gene WT1 or a peptide composed of 7-30 contiguous amino acids containing an anchor amino acid for binding to major histocompatibility complex (MHC) class I in said amino acid sequence, and a vaccine comprising ... 12/01/05 - 20050266013 - Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use Polypeptides capable of forming antigen binding structures specific for Rhesus D antigens include the sequences indicated in the FIGS. 1a to 16b. The obtained polypeptides, being Fab fragments, MAY be used directly as an active ingredient in pharmaceutical and diagnostic compositions. The Fab and their DNA sequences can also be ... 11/24/05 - 20050260219 - Carboxypeptidases b from anopheles gambiae. compositions comprising them, vaccine applications and use as therapeutical targets The present invention provides two carboxypeptidase B enzymes from Anopheles gambiae and homologs thereof. The present invention also provides compositions and vaccines containing the carboxypeptidase B enzymes, as well as antibodies directed thereto and various methods of using the same. The methods of the present invention include a method of ... 11/24/05 - 20050260218 - House dust mite allergen, der f vii, and uses therefor Isolated nucleic acids encoding allergens of the species Dermatophagoides pteronyssinus and Dermatophagoides farinae, Der p VII and Der f VII, respectively, are disclosed. A cDNA encoding a peptide having a Der p VII activity and a predicted molecular weight of about 22, 177 daltons is described. A cDNA encoding a ... 11/24/05 - 20050260217 - Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 WT1 polypeptides in combination with one or more immunostimulants, either independently or co-encapsulated with biodegradable polymeric microspheres. Such compositions may be used, for example, for ... 11/17/05 - 20050255122 - Prevention and treatment of amyloidogenic disease The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is ... 11/10/05 - 20050249743 - Isolated peptides which bind to hla-a24 molecules and uses thereof Peptides which consist of amino acid sequences found in MAGE-4 bind to HLA-A24 to form T cell epitopes. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention. ... 11/10/05 - 20050249742 - Compositions and methods for modulating a cytotoxic t lymphocyte immune response The present invention provides compositions and methods for the treatment and prevention of immune disorders. ... 11/10/05 - 20050249741 - Novel semaphorin gene: semaphorin w The present invention provides Semaphorin W inhibiting neurite outgrowth, and a gene therefor, as well as other Semaphorins hybridizing to said Semaphorin W gene, modified proteins or partial peptides of said Semaphorin W, antibodies against said Semaphorin W, antisense nucleotides against said Semaphorin W gene, and the use of such ... 11/03/05 - 20050244422 - Methods for delivering mbd peptide-linked agent into cells under conditions of cellular stress The present invention is related to methods of delivering MBD peptide-linked agents into live cells. The methods described herein comprise contacting MBD peptide-linked agents to live cells under a condition of cellular stress. The methods of the invention may be used for therapeutic or diagnostic purposes. ... 11/03/05 - 20050244421 - Compositions and methods for modulating immune response A method of modulating reactivity of a T cell population of a mammal comprises contacting the T cell population with an immunogenic dose of an antigenic peptide having a sequence that derives from a tissue specific expressed allelic protein variant from an individual of a specific species, wherein the tissue ... 10/27/05 - 20050238653 - Pharmaceutical compositions containing extracted mhc molecules, for stimulation of the immune system Allo-, iso- and xenoantigens, chosen from histocompatibility molecules obtained by extraction from homogenates of tissues or cells with Nonidet P40 or 1 N HClO4, are disclosed for use as a medicament for stimulation of the immune system of man and mammals, and in particular for cancer therapy. ... 10/20/05 - 20050232932 - Compositions and methods for dendritic cell-based immunotherapy Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component derived from the intracellular domain of the HER-2 protein. Also disclosed are immunostimulatory compositions comprising dendritic cells ... 10/20/05 - 20050232931 - Preparation and application of anti-tumor bifunctional fusion proteins Provided herein is a chimeric protein, which chimeric protein comprises a Flt3 ligand, or a |